Figure 3.

Frequency of patients with MRD after EOI1 correlates with cytogenetic and molecular risk status and MRD status stratifies high- and standard-risk patient RR. (A) Frequency of MRD after EOI1 among all patients, and distribution among low-, intermediate-, and high-risk groups. Presence of MRD after EOI1 stratifies RR of patients with cytogenetic/molecular high-risk (B) and standard-risk (C), but not those with low-risk status (D). The details of cytogenetic and molecular risk stratification were described in “Methods.”